当前位置：
X-MOL 学术
›
Lancet HIV
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Vaccine boosts: balancing response magnitude and character.
The Lancet HIV ( IF 12.8 ) Pub Date : 2020-02-06 , DOI: 10.1016/s2352-3018(19)30435-7 Andrew R Crowley 1 , Margaret E Ackerman 2
The Lancet HIV ( IF 12.8 ) Pub Date : 2020-02-06 , DOI: 10.1016/s2352-3018(19)30435-7 Andrew R Crowley 1 , Margaret E Ackerman 2
Affiliation
|
With 1·7 million new HIV-1 infections occurring annually, an effective vaccine is still needed. Although the ALVAC-HIV and AIDSVAX B/E gp120 Env regimen used in the RV144 clinical trial provided only modest protection of about 30%, it offered a blueprint for future HIV vaccination regimens. One approach that has been assessed for its potential to improve upon RV144 is the delivery of additional immunisations with the goal of boosting the initial immune response and eliciting the immunological features that previously correlated with protection.
中文翻译：
加强疫苗接种：平衡反应强度和特征。
每年有1·700万新的HIV-1感染，仍然需要有效的疫苗。尽管RV144临床试验中使用的ALVAC-HIV和AIDSVAX B / E gp120 Env方案仅提供约30％的适度保护，但它为将来的HIV疫苗接种方案提供了蓝图。已评估其在RV144上改善的潜力的一种方法是提供其他免疫，目的是增强初始免疫应答并激发先前与保护相关的免疫学特征。
更新日期：2020-04-01
中文翻译：
加强疫苗接种：平衡反应强度和特征。
每年有1·700万新的HIV-1感染，仍然需要有效的疫苗。尽管RV144临床试验中使用的ALVAC-HIV和AIDSVAX B / E gp120 Env方案仅提供约30％的适度保护，但它为将来的HIV疫苗接种方案提供了蓝图。已评估其在RV144上改善的潜力的一种方法是提供其他免疫，目的是增强初始免疫应答并激发先前与保护相关的免疫学特征。
京公网安备 11010802027423号